Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors

Bioorg Med Chem Lett. 2001 Jun 4;11(11):1465-8. doi: 10.1016/s0960-894x(01)00259-1.

Abstract

A series of novel matrix metalloproteinase inhibitors is described in which selectivity between MMP and 'sheddase' activity has been achieved and which demonstrate potent in vivo activity in models of arthritis and cancer.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Arthritis, Experimental / drug therapy
  • Disease Models, Animal
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Hydroxamic Acids / chemical synthesis
  • Hydroxamic Acids / pharmacology*
  • Hydroxamic Acids / therapeutic use
  • Matrix Metalloproteinase Inhibitors*
  • Melanoma, Experimental / drug therapy
  • Mice

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Hydroxamic Acids
  • Matrix Metalloproteinase Inhibitors
  • marimastat